Holbaek, Denmark: Pharmacosmos is pleased to announce that the National Healthcare Security Administration (NHSA) in China has granted Monofer® national reimbursement.
Monofer® is an intravenous (IV) iron indicated in China for the treatment of iron deficiency (ID) and iron deficiency anemia (IDA) when oral iron preparations are ineffective or cannot be used; or where there is a clinical need to deliver iron rapidly. IDA is a frequent condition for patients across various therapeutic areas and the general prevalence in the Chinese population is estimated to be approximately 10%1. The IV iron market in China is one of the largest in the world.
Monofer® was the first novel high dose IV iron to be approved in China and is now the first high dose IV iron to receive reimbursement.
“We are very pleased to receive the reimbursement approval for Monofer® in China” said Tobias S. Christensen, President and CEO of Pharmacosmos A/S. “Through our own affiliate, we are in a unique position to make a difference for the more than 100 million patients suffering from IDA in China”.
“Since the launch, Monofer® has been included in a number of local clinical guidelines”, said Kathy Liu Managing Director of Pharmacosmos in China. “With this reimbursement approval, more patients suffering from iron deficiency and iron deficiency anemia will benefit from Monofer®”
For more information, please contact:
Christian Lundquist Madsen, Head of Global Marketing
+45 5948 5959 firstname.lastname@example.org
 School of Public Health, Fudan University. Research report on the disease burden and diagnosis and treatment status of iron deficiency anemia in China. 2012
Monofer® (ferric derisomaltose) is an iron-carbohydrate complex for intravenous administration. Monofer® is marketed in more than 30 countries worldwide for the treatment of iron deficiency and iron deficiency anaemia. Monofer® is manufactured by Pharmacosmos A/S, Denmark.
Pharmacosmos Group, headquartered in Holbaek, Denmark, and founded in 1965, is a highly specialised company focused on carbohydrate chemistry and a global leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anaemia. With companies in the UK, Nordics, Germany, the USA, and China, as well as through partners, Pharmacosmos markets its products around the world. With a strong and ongoing commitment to R&D, Pharmacosmos is able to leverage a unique carbohydrate production platform along with deep expertise in the synthesis of iron-carbohydrate complexes. The Pharmacosmos Group has approximately 500 employees.
You are now leaving Pharmacosmos.com. The website you are about to visit is a Pharmacosmos subsidary.
Do you wish to proceed?